ceftriaxone Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antibiotics, cefalosporanic acid derivatives 564 73384-59-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • ceftriaxone sodium hydrate
  • ceftriaxone
  • biotrakson
  • rocefin
  • rocephalin
  • rophex
  • ceftriaxone sodium
A broad-spectrum cephalosporin antibiotic and cefotaxime derivative with a very long half-life and high penetrability to meninges, eyes and inner ears.
  • Molecular weight: 554.57
  • Formula: C18H18N8O7S3
  • CLOGP: 0.02
  • LIPINSKI: 2
  • HAC: 15
  • HDO: 4
  • TPSA: 208.98
  • ALOGS: -3.72
  • ROTB: 8

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
2 g P
2 g P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 400 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 46 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 120.27 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 0 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.12 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 0.22 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.10 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 7.60 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Dec. 21, 1984 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug reaction with eosinophilia and systemic symptoms 628.04 12.07 359 39807 32441 53276459
Toxic epidermal necrolysis 352.28 12.07 220 39946 23330 53285570
Acute generalised exanthematous pustulosis 317.54 12.07 155 40011 10126 53298774
Acute kidney injury 294.75 12.07 613 39553 253255 53055645
Pseudocholelithiasis 247.71 12.07 40 40126 0 53308900
Rash maculo-papular 215.74 12.07 179 39987 29570 53279330
Multiple organ dysfunction syndrome 210.76 12.07 234 39932 55443 53253457
Rheumatoid arthritis 202.36 12.07 8 40158 314523 52994377
Eosinophilia 201.41 12.07 150 40016 21185 53287715
Fatigue 200.65 12.07 155 40011 730351 52578549
Jarisch-Herxheimer reaction 196.87 12.07 46 40120 267 53308633
Off label use 171.14 12.07 755 39411 471457 52837443
Pyrexia 166.49 12.07 671 39495 402522 52906378
Agranulocytosis 162.07 12.07 138 40028 23611 53285289
Pain 154.85 12.07 130 40036 588268 52720632
Hepatitis 152.16 12.07 156 40010 33738 53275162
Recalled product administered 149.82 12.07 40 40126 426 53308474
Cholestasis 145.28 12.07 141 40025 28554 53280346
Septic shock 144.75 12.07 205 39961 62024 53246876
Joint swelling 141.22 12.07 9 40157 234629 53074271
Cholelithiasis 139.44 12.07 163 40003 40801 53268099
Stevens-Johnson syndrome 138.19 12.07 128 40038 24454 53284446
Electrocardiogram QT prolonged 135.92 12.07 189 39977 56214 53252686
Clostridium difficile colitis 133.12 12.07 114 40052 19651 53289249
Haemolytic anaemia 132.51 12.07 88 40078 10351 53298549
Drug interaction 132.43 12.07 414 39752 218915 53089985
Anaphylactic shock 130.88 12.07 118 40048 21775 53287125
Tubulointerstitial nephritis 127.37 12.07 103 40063 16401 53292499
Factor V inhibition 123.29 12.07 29 40137 174 53308726
Drug intolerance 114.89 12.07 11 40155 205482 53103418
Arthralgia 105.01 12.07 106 40060 439677 52869223
Alopecia 105.00 12.07 24 40142 234559 53074341
Postrenal failure 104.89 12.07 23 40143 95 53308805
Headache 99.48 12.07 157 40009 536664 52772236
Premature delivery 97.48 12.07 109 40057 25995 53282905
Hepatocellular injury 94.91 12.07 115 40051 29871 53279029
Arthropathy 92.92 12.07 3 40163 141450 53167450
Abdominal discomfort 88.77 12.07 28 40138 221034 53087866
Product dose omission issue 86.95 12.07 19 40147 191601 53117299
Fall 84.80 12.07 87 40079 358353 52950547
Leukocytosis 83.44 12.07 98 40068 24636 53284264
Weight increased 80.21 12.07 27 40139 204540 53104360
Status epilepticus 79.45 12.07 76 40090 15108 53293792
Pseudomembranous colitis 76.55 12.07 41 40125 3250 53305650
Drug-induced liver injury 74.98 12.07 101 40065 29132 53279768
Acute respiratory distress syndrome 74.68 12.07 90 40076 23242 53285658
Sepsis 74.46 12.07 261 39905 146168 53162732
Thrombocytopenia 72.91 12.07 250 39916 138477 53170423
Therapeutic product effect decreased 72.16 12.07 6 40160 125649 53183251
Swelling 71.88 12.07 27 40139 191078 53117822
Hepatitis cholestatic 71.68 12.07 52 40114 7047 53301853
Clostridium difficile infection 70.97 12.07 96 40070 27797 53281103
Respiratory failure 70.24 12.07 200 39966 100312 53208588
Contraindicated product administered 68.99 12.07 10 40156 135619 53173281
Nasopharyngitis 66.16 12.07 31 40135 192264 53116636
Altered state of consciousness 65.52 12.07 87 40079 24749 53284151
Long QT syndrome 65.47 12.07 37 40129 3259 53305641
Haemophagocytic lymphohistiocytosis 64.17 12.07 54 40112 9083 53299817
Peripheral swelling 63.88 12.07 38 40128 206070 53102830
Erythema 63.43 12.07 260 39906 156709 53152191
Exposure during pregnancy 62.98 12.07 222 39944 124638 53184262
Glossodynia 62.90 12.07 3 40163 100288 53208612
Pemphigus 62.50 12.07 4 40162 104027 53204873
Enterococcal infection 61.99 12.07 49 40117 7549 53301351
Insomnia 61.57 12.07 32 40134 187040 53121860
Choreoathetosis 61.01 12.07 20 40146 451 53308449
Bronchopulmonary aspergillosis 60.42 12.07 51 40115 8614 53300286
Cardiac arrest 59.34 12.07 180 39986 93487 53215413
Dermatitis exfoliative 58.84 12.07 43 40123 5893 53303007
Dizziness 58.80 12.07 120 40046 372139 52936761
Injection site pain 58.51 12.07 8 40158 113383 53195517
Pain in extremity 57.90 12.07 78 40088 284972 53023928
Systemic lupus erythematosus 57.75 12.07 12 40154 125402 53183498
Pneumococcal infection 57.52 12.07 19 40147 439 53308461
Linear IgA disease 57.19 12.07 26 40140 1444 53307456
Encephalopathy 56.11 12.07 100 40066 36708 53272192
Transaminases increased 55.39 12.07 89 40077 30043 53278857
Myasthenia gravis crisis 54.82 12.07 18 40148 408 53308492
Neutropenia 54.61 12.07 251 39915 158934 53149966
Toxic encephalopathy 54.41 12.07 41 40125 5886 53303014
Torsade de pointes 53.23 12.07 57 40109 12948 53295952
Psoriasis 50.43 12.07 4 40162 87085 53221815
Symmetrical drug-related intertriginous and flexural exanthema 50.10 12.07 16 40150 331 53308569
Cholecystitis 49.09 12.07 59 40107 15187 53293713
Wound 48.33 12.07 6 40160 91551 53217349
Tachycardia 48.32 12.07 185 39981 108027 53200873
Hypoxia 48.20 12.07 120 40046 55560 53253340
Tachypnoea 47.24 12.07 59 40107 15795 53293105
Red man syndrome 46.31 12.07 21 40145 1159 53307741
Depression 46.03 12.07 42 40124 183010 53125890
Low birth weight baby 45.64 12.07 38 40128 6299 53302601
Rash morbilliform 45.05 12.07 29 40137 3234 53305666
Urticaria 44.92 12.07 212 39954 135673 53173227
Influenza B virus test positive 44.76 12.07 15 40151 363 53308537
Alveolitis 44.65 12.07 27 40139 2697 53306203
Contusion 44.45 12.07 14 40152 110718 53198182
Acinetobacter infection 44.42 12.07 22 40144 1481 53307419
Anaphylactic reaction 43.62 12.07 119 40047 58207 53250693
Dermatitis bullous 42.97 12.07 41 40125 8122 53300778
Nausea 42.12 12.07 366 39800 755725 52553175
No adverse event 42.06 12.07 92 40074 39173 53269727
Acute respiratory failure 41.46 12.07 80 40086 31178 53277722
Pancytopenia 41.04 12.07 156 40010 90772 53218128
Drug resistance 40.92 12.07 62 40104 19900 53289000
Gait disturbance 40.46 12.07 36 40130 158806 53150094
Cholangitis 40.19 12.07 32 40134 4981 53303919
Pyuria 40.02 12.07 22 40144 1836 53307064
Metabolic acidosis 39.72 12.07 94 40072 42148 53266752
Weight decreased 39.42 12.07 73 40093 234875 53074025
Malaise 39.23 12.07 138 40028 357479 52951421
Death 39.08 12.07 138 40028 357094 52951806
Muscle spasms 38.81 12.07 27 40139 134768 53174132
Haemolysis 38.78 12.07 35 40131 6461 53302439
Nosocomial infection 38.68 12.07 21 40145 1710 53307190
Pleocytosis 37.87 12.07 15 40151 590 53308310
Musculoskeletal stiffness 37.84 12.07 23 40143 123345 53185555
Cross sensitivity reaction 37.64 12.07 22 40144 2065 53306835
Hypertransaminasaemia 37.35 12.07 28 40138 3988 53304912
Pathogen resistance 36.54 12.07 34 40132 6526 53302374
Klebsiella infection 36.49 12.07 37 40129 7889 53301011
Injection site erythema 36.37 12.07 7 40159 77242 53231658
Premature baby 35.73 12.07 58 40108 19743 53289157
Hydronephrosis 35.35 12.07 39 40127 9157 53299743
Renal failure 34.99 12.07 179 39987 118273 53190627
Encephalitis 34.61 12.07 36 40130 7908 53300992
SJS-TEN overlap 33.72 12.07 11 40155 244 53308656
Stenotrophomonas infection 33.17 12.07 19 40147 1717 53307183
CSF measles antibody positive 32.82 12.07 8 40158 57 53308843
Meningitis bacterial 32.44 12.07 17 40149 1289 53307611
Pneumonia 32.31 12.07 457 39709 406712 52902188
Guillain-Barre syndrome 32.21 12.07 25 40141 3750 53305150
Rubella antibody positive 32.01 12.07 8 40158 64 53308836
Discomfort 31.88 12.07 16 40150 95456 53213444
Arthritis 31.69 12.07 13 40153 87285 53221615
Leukaemoid reaction 31.54 12.07 10 40156 202 53308698
Product use in unapproved indication 31.31 12.07 167 39999 112122 53196778
Hepatic cytolysis 31.28 12.07 34 40132 7851 53301049
Migraine 30.82 12.07 11 40155 80406 53228494
Laryngeal stenosis 30.55 12.07 14 40152 792 53308108
Enterobacter infection 30.54 12.07 19 40147 1997 53306903
Respiratory distress 30.43 12.07 74 40092 33753 53275147
COVID-19 pneumonia 30.23 12.07 32 40134 7171 53301729
Drug ineffective for unapproved indication 29.92 12.07 55 40111 20665 53288235
Leukopenia 29.88 12.07 122 40044 73341 53235559
Lower respiratory tract infection 29.27 12.07 16 40150 90965 53217935
Blood brain barrier defect 28.94 12.07 8 40158 98 53308802
Haemodynamic instability 28.89 12.07 34 40132 8560 53300340
Lip oedema 28.86 12.07 23 40143 3584 53305316
Oliguria 28.52 12.07 35 40131 9203 53299697
Feeling abnormal 28.48 12.07 36 40130 135265 53173635
Osteoarthritis 28.12 12.07 9 40157 70477 53238423
Pyelonephritis acute 28.08 12.07 25 40141 4534 53304366
Blood pressure increased 27.91 12.07 39 40127 140440 53168460
Clostridium test positive 27.91 12.07 19 40147 2327 53306573
Intentional overdose 27.87 12.07 8 40158 67197 53241703
Angioedema 27.70 12.07 82 40084 41994 53266906
Alanine aminotransferase increased 27.59 12.07 143 40023 94952 53213948
International normalised ratio increased 26.75 12.07 88 40078 47673 53261227
Autoimmune haemolytic anaemia 26.51 12.07 24 40142 4447 53304453
Bile duct stone 26.44 12.07 22 40144 3643 53305257
Rash erythematous 26.38 12.07 75 40091 37548 53271352
CSF protein increased 26.07 12.07 11 40155 510 53308390
Myocardial infarction 25.91 12.07 22 40144 99332 53209568
Abdominal pain upper 25.85 12.07 54 40112 166237 53142663
Weber tuning fork test abnormal 25.46 12.07 7 40159 84 53308816
Back pain 25.24 12.07 91 40075 234156 53074744
Pelvic inflammatory disease 25.22 12.07 16 40150 1740 53307160
Mobility decreased 25.14 12.07 13 40153 76258 53232642
Bacteriuria 25.11 12.07 12 40154 747 53308153
Aspartate aminotransferase increased 24.82 12.07 127 40039 83902 53224998
Intervertebral discitis 24.78 12.07 19 40147 2798 53306102
Maternal exposure during pregnancy 24.73 12.07 201 39965 155438 53153462
Gastrointestinal disorder 24.63 12.07 19 40147 89985 53218915
Product use issue 24.62 12.07 42 40124 139542 53169358
Immune reconstitution inflammatory syndrome 24.54 12.07 27 40139 6319 53302581
Shock 24.53 12.07 54 40112 23085 53285815
Factor V deficiency 24.46 12.07 7 40159 98 53308802
Blood creatinine increased 24.46 12.07 125 40041 82537 53226363
Hepatitis infectious mononucleosis 24.40 12.07 7 40159 99 53308801
Thunderclap headache 24.21 12.07 8 40158 185 53308715
Eosinophilic pneumonia 24.09 12.07 17 40149 2205 53306695
Fibrin D dimer increased 23.92 12.07 23 40143 4600 53304300
Cyanosis 23.82 12.07 44 40122 16595 53292305
Hyporesponsive to stimuli 23.80 12.07 13 40153 1071 53307829
Gastroenteritis clostridial 23.75 12.07 11 40155 638 53308262
Clostridium colitis 23.67 12.07 16 40150 1936 53306964
Systemic inflammatory response syndrome 23.50 12.07 25 40141 5635 53303265
Face oedema 23.48 12.07 49 40117 20191 53288709
Hepatic function abnormal 23.43 12.07 71 40095 36828 53272072
Foetal exposure during pregnancy 23.18 12.07 68 40098 34647 53274253
Pyelonephritis 22.94 12.07 43 40123 16394 53292506
Organic brain syndrome 22.91 12.07 8 40158 220 53308680
Sinusitis 22.78 12.07 59 40107 168505 53140395
Neurotoxicity 22.49 12.07 41 40125 15308 53293592
Electrolyte imbalance 22.24 12.07 46 40120 18838 53290062
Ill-defined disorder 22.20 12.07 5 40161 49439 53259461
Haemostasis 22.19 12.07 8 40158 242 53308658
Hypertension 22.08 12.07 91 40075 225340 53083560
Meningitis 22.06 12.07 26 40140 6555 53302345
Renal papillary necrosis 22 12.07 8 40158 248 53308652
Suicidal ideation 21.98 12.07 9 40157 60502 53248398
Hypokalaemia 21.96 12.07 136 40030 96381 53212519
Drug abuse 21.84 12.07 11 40155 65515 53243385
Stomatitis 21.84 12.07 25 40141 98133 53210767
Abdominal wall haematoma 21.63 12.07 18 40148 2980 53305920
Myopathy toxic 21.62 12.07 9 40157 403 53308497
Drug eruption 21.62 12.07 54 40112 25040 53283860
Infusion related reaction 21.52 12.07 54 40112 155903 53152997
Type I hypersensitivity 21.38 12.07 17 40149 2640 53306260
Renal tubular necrosis 21.35 12.07 34 40132 11385 53297515
Meningism 21.33 12.07 9 40157 417 53308483
Cardiogenic shock 21.08 12.07 43 40123 17439 53291461
Stress cardiomyopathy 21.06 12.07 29 40137 8533 53300367
Nephropathy toxic 21.04 12.07 29 40137 8543 53300357
Rash 21.03 12.07 461 39705 445730 52863170
Erythema multiforme 21.01 12.07 32 40134 10317 53298583
Unresponsive to stimuli 20.92 12.07 64 40102 33362 53275538
Aspergillus infection 20.91 12.07 27 40139 7469 53301431
Hypotension 20.84 12.07 287 39879 253789 53055111
Anxiety 20.80 12.07 77 40089 196627 53112273
Palpitations 20.74 12.07 28 40138 102320 53206580
Hospitalisation 20.72 12.07 14 40152 70998 53237902
Iris transillumination defect 20.65 12.07 6 40160 89 53308811
Endocarditis 20.64 12.07 23 40143 5461 53303439
Intravascular haemolysis 20.61 12.07 8 40158 298 53308602
Veillonella infection 20.59 12.07 5 40161 35 53308865
Laryngeal mass 20.59 12.07 5 40161 35 53308865
Hyperthyroidism 20.54 12.07 36 40130 13037 53295863
Anuria 20.51 12.07 35 40131 12405 53296495
Haemodialysis 20.40 12.07 30 40136 9374 53299526
Cholangitis acute 20.37 12.07 9 40157 467 53308433
Erythema nodosum 20.28 12.07 20 40146 4125 53304775
Hepatosplenomegaly 20.03 12.07 16 40150 2502 53306398
Inflammatory marker increased 20 12.07 24 40142 6166 53302734
Dry mouth 19.85 12.07 10 40156 59540 53249360
Otitis media acute 19.63 12.07 11 40155 953 53307947
Gastrooesophageal reflux disease 19.55 12.07 20 40146 82643 53226257
Acquired haemophilia 19.55 12.07 11 40155 961 53307939
Balance disorder 19.35 12.07 16 40150 73191 53235709
Bronchial obstruction 19.29 12.07 13 40153 1565 53307335
Nasal congestion 19.23 12.07 8 40158 53279 53255621
Multiple sclerosis relapse 19.23 12.07 5 40161 44848 53264052
Pneumonia necrotising 19.04 12.07 8 40158 367 53308533
COVID-19 18.92 12.07 66 40100 36822 53272078
Toxicity to various agents 18.89 12.07 93 40073 219505 53089395
Encephalitis brain stem 18.89 12.07 6 40160 122 53308778
Treatment failure 18.87 12.07 43 40123 128360 53180540
Nocardiosis 18.81 12.07 14 40152 1973 53306927
Postpartum sepsis 18.76 12.07 4 40162 14 53308886
Coagulation factor deficiency 18.76 12.07 4 40162 14 53308886
Normal newborn 18.70 12.07 25 40141 7154 53301746
Bronchopleural fistula 18.70 12.07 7 40159 236 53308664
Cataract 18.65 12.07 7 40159 49613 53259287
Morganella infection 18.61 12.07 9 40157 575 53308325
Anti factor V antibody 18.58 12.07 3 40163 0 53308900
Liver injury 18.45 12.07 47 40119 22056 53286844
Memory impairment 18.41 12.07 22 40144 84735 53224165
Myocarditis 18.35 12.07 27 40139 8441 53300459
Unmasking of previously unidentified disease 18.30 12.07 10 40156 825 53308075
Hypercreatininaemia 18.11 12.07 8 40158 415 53308485
Septic pulmonary embolism 18.11 12.07 5 40161 61 53308839
Condition aggravated 18.02 12.07 319 39847 296815 53012085
Eosinophilic pneumonia acute 17.98 12.07 8 40158 422 53308478
Normochromic anaemia 17.90 12.07 7 40159 266 53308634
Coagulation factor decreased 17.89 12.07 5 40161 64 53308836
Respiratory acidosis 17.81 12.07 23 40143 6365 53302535
Influenza like illness 17.76 12.07 12 40154 60847 53248053
Hypoaesthesia 17.62 12.07 47 40119 132948 53175952
Partial seizures 17.61 12.07 21 40145 5359 53303541
Hypofibrinogenaemia 17.61 12.07 11 40155 1164 53307736
Disseminated intravascular coagulation 17.59 12.07 43 40123 19676 53289224
Cerebral artery stenosis 17.58 12.07 8 40158 445 53308455
Dermatitis exfoliative generalised 17.52 12.07 17 40149 3438 53305462
Helicobacter infection 17.44 12.07 4 40162 39065 53269835
Conjunctival hyperaemia 17.32 12.07 14 40152 2225 53306675
Transverse sinus thrombosis 17.25 12.07 9 40157 676 53308224
Purpura 17.20 12.07 30 40136 10823 53298077
Blood pressure fluctuation 17.15 12.07 3 40163 35467 53273433
Asymptomatic bacteriuria 17.15 12.07 7 40159 298 53308602
Jaundice 17.10 12.07 56 40110 30257 53278643
Infantile apnoea 17.07 12.07 10 40156 942 53307958
Pseudophaeochromocytoma 17.03 12.07 5 40161 77 53308823
Dyspepsia 17.00 12.07 20 40146 77580 53231320
Hyperlactacidaemia 16.90 12.07 15 40151 2710 53306190
Encephalitis autoimmune 16.62 12.07 11 40155 1285 53307615
Drug hypersensitivity 16.52 12.07 286 39880 264956 53043944
Red blood cell agglutination 16.50 12.07 3 40163 3 53308897
Antibiotic associated colitis 16.50 12.07 3 40163 3 53308897
Skin test positive 16.25 12.07 9 40157 762 53308138
Cholestatic liver injury 16.22 12.07 14 40152 2437 53306463
Relapsing fever 15.98 12.07 6 40160 204 53308696
Stomatococcal infection 15.96 12.07 5 40161 97 53308803
Hyperthermia malignant 15.89 12.07 9 40157 796 53308104
Musculoskeletal pain 15.82 12.07 20 40146 75180 53233720
Impaired healing 15.80 12.07 15 40151 64190 53244710
Agitation 15.52 12.07 86 40080 58540 53250360
Hyperbilirubinaemia 15.50 12.07 29 40137 11040 53297860
Gamma-glutamyltransferase increased 15.48 12.07 58 40108 33497 53275403
Nephritis 15.47 12.07 13 40153 2182 53306718
Injection site pruritus 15.41 12.07 6 40160 41583 53267317
Wound haemorrhage 15.41 12.07 13 40153 2194 53306706
Sleep disorder 15.39 12.07 13 40153 58857 53250043
Haemoperitoneum 15.33 12.07 14 40152 2623 53306277
Post treatment Lyme disease syndrome 15.29 12.07 3 40163 6 53308894
CSF oligoclonal band present 15.28 12.07 5 40161 112 53308788
Herpes zoster 15.25 12.07 20 40146 73999 53234901
Type IV hypersensitivity reaction 15.09 12.07 14 40152 2678 53306222
Hyperglycaemia 15.07 12.07 65 40101 40019 53268881
Cerebral aspergillosis 15.06 12.07 7 40159 409 53308491
Amoebic brain abscess 14.97 12.07 3 40163 7 53308893
Overlap syndrome 14.87 12.07 8 40158 640 53308260
Vision blurred 14.87 12.07 26 40140 85578 53223322
Pneumonia mycoplasmal 14.84 12.07 9 40157 904 53307996
Neisseria infection 14.78 12.07 4 40162 45 53308855
Dry skin 14.78 12.07 8 40158 45752 53263148
Brain abscess 14.73 12.07 12 40154 1929 53306971
Folliculitis 14.66 12.07 3 40163 31706 53277194
Inappropriate schedule of product administration 14.65 12.07 21 40145 74857 53234043
Pneumonia pneumococcal 14.63 12.07 12 40154 1948 53306952
Hepatitis acute 14.59 12.07 25 40141 8891 53300009
Hypoalbuminaemia 14.51 12.07 28 40138 10908 53297992
Stress 14.45 12.07 13 40153 57071 53251829
Hemianopia 14.39 12.07 9 40157 955 53307945
Haematoma 14.39 12.07 57 40109 33787 53275113
Anoxia 14.34 12.07 6 40160 272 53308628
Vitamin K deficiency 14.33 12.07 7 40159 457 53308443
Toxic skin eruption 14.31 12.07 31 40135 13108 53295792
Clostridial infection 14.11 12.07 17 40149 4385 53304515
Candida test positive 14.05 12.07 9 40157 995 53307905
Thrombosis 14.05 12.07 15 40151 60778 53248122
Lemierre syndrome 14 12.07 5 40161 147 53308753
Eyelid oedema 13.98 12.07 27 40139 10527 53298373
Mixed liver injury 13.96 12.07 16 40150 3917 53304983
Dry eye 13.95 12.07 4 40162 33640 53275260
Ventricular dysfunction 13.95 12.07 14 40152 2949 53305951
Fibromyalgia 13.81 12.07 8 40158 44067 53264833
Escherichia infection 13.78 12.07 29 40137 12021 53296879
Microangiopathic haemolytic anaemia 13.77 12.07 7 40159 498 53308402
Foetal death 13.73 12.07 25 40141 9322 53299578
Visual impairment 13.73 12.07 21 40145 72891 53236009
Anti-platelet antibody positive 13.72 12.07 4 40162 60 53308840
Hypertensive heart disease 13.69 12.07 13 40153 2560 53306340
Pruritus 13.62 12.07 303 39863 293529 53015371
Systemic candida 13.58 12.07 14 40152 3043 53305857
Bronchospasm 13.55 12.07 35 40131 16563 53292337
Adverse event 13.52 12.07 7 40159 41054 53267846
Alpha 1 microglobulin increased 13.49 12.07 4 40162 64 53308836
Acute hepatic failure 13.39 12.07 35 40131 16685 53292215
Orthostatic hypotension 13.37 12.07 3 40163 29750 53279150
Ear pain 13.32 12.07 3 40163 29670 53279230
Kidney enlargement 13.20 12.07 7 40159 544 53308356
Hypoxic-ischaemic encephalopathy 13.08 12.07 16 40150 4192 53304708
Ureterolithiasis 13.07 12.07 11 40155 1849 53307051
Fluid retention 13.05 12.07 13 40153 54388 53254512
Leukoencephalopathy 13.03 12.07 16 40150 4208 53304692
Chemotherapeutic drug level increased 12.97 12.07 5 40161 183 53308717
Bacteraemia 12.91 12.07 33 40133 15516 53293384
Surgery 12.89 12.07 4 40162 31960 53276940
Tracheobronchitis 12.88 12.07 9 40157 1150 53307750
Ventricular fibrillation 12.83 12.07 28 40138 11897 53297003
Hyperthermia 12.69 12.07 23 40143 8546 53300354
Coombs negative haemolytic anaemia 12.69 12.07 5 40161 194 53308706
Erysipelas 12.65 12.07 21 40145 7280 53301620
Base excess 12.61 12.07 4 40162 81 53308819
Neuropathy peripheral 12.53 12.07 38 40128 103149 53205751
Brain herniation 12.50 12.07 14 40152 3342 53305558
Petechiae 12.49 12.07 30 40136 13575 53295325
Septic embolus 12.49 12.07 8 40158 885 53308015
Superior sagittal sinus thrombosis 12.48 12.07 8 40158 886 53308014
Human herpesvirus 6 infection reactivation 12.42 12.07 4 40162 85 53308815
Hyperpyrexia 12.37 12.07 14 40152 3380 53305520
Chorioretinitis 12.37 12.07 6 40160 386 53308514
Stridor 12.36 12.07 14 40152 3383 53305517
Hepatic enzyme increased 12.31 12.07 51 40115 126144 53182756
Upper respiratory tract infection bacterial 12.29 12.07 4 40162 88 53308812
Muscle haemorrhage 12.27 12.07 14 40152 3409 53305491
CSF cell count increased 12.23 12.07 3 40163 22 53308878
Coronary artery disease 12.10 12.07 5 40161 33432 53275468

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Off label use 410.38 12.16 1114 42704 305206 32164502
Drug reaction with eosinophilia and systemic symptoms 306.58 12.16 292 43526 32193 32437515
Postrenal failure 296.15 12.16 77 43741 376 32469332
Jarisch-Herxheimer reaction 249.18 12.16 67 43751 381 32469327
Rash maculo-papular 169.79 12.16 199 43619 27823 32441885
Pseudocholelithiasis 162.72 12.16 29 43789 0 32469708
Acute kidney injury 146.94 12.16 780 43038 292688 32177020
Cholelithiasis 142.75 12.16 158 43660 20754 32448954
Fatigue 141.55 12.16 159 43659 350542 32119166
Acute generalised exanthematous pustulosis 138.81 12.16 95 43723 6518 32463190
Death 137.09 12.16 190 43628 382327 32087381
Cholestasis 133.15 12.16 173 43645 26860 32442848
Eosinophilia 132.84 12.16 166 43652 24792 32444916
Appendicolith 130.17 12.16 70 43748 3095 32466613
Toxic epidermal necrolysis 127.65 12.16 148 43670 20445 32449263
Pyrexia 124.69 12.16 796 43022 319172 32150536
Hepatocellular injury 124.65 12.16 162 43656 25156 32444552
Hypertransaminasaemia 119.79 12.16 73 43745 4101 32465607
Anaphylactic shock 105.03 12.16 115 43703 14919 32454789
Toxic encephalopathy 100.92 12.16 70 43748 4907 32464801
Multiple organ dysfunction syndrome 98.59 12.16 260 43558 69594 32400114
Agranulocytosis 97.02 12.16 138 43680 23339 32446369
Hepatitis 96.05 12.16 138 43680 23555 32446153
Ureterolithiasis 95.10 12.16 49 43769 1983 32467725
Anaphylactic reaction 93.22 12.16 155 43663 30017 32439691
Product dose omission issue 90.10 12.16 15 43803 102560 32367148
Cardiogenic shock 86.18 12.16 122 43696 20540 32449168
Recalled product administered 86.01 12.16 30 43788 446 32469262
Haemolytic anaemia 85.76 12.16 88 43730 10596 32459112
Appendicitis 85.47 12.16 81 43737 8856 32460852
Pathogen resistance 84.93 12.16 83 43735 9427 32460281
Long QT syndrome 83.25 12.16 49 43769 2582 32467126
Depression 81.34 12.16 16 43802 97044 32372664
Drug-induced liver injury 80.27 12.16 128 43690 23935 32445773
Drug abuse 79.43 12.16 8 43810 80235 32389473
Dizziness 79.03 12.16 100 43718 209518 32260190
Fall 78.86 12.16 89 43729 196112 32273596
Clostridium difficile colitis 75.72 12.16 95 43723 14236 32455472
Myocardial infarction 74.78 12.16 38 43780 125638 32344070
Septic shock 70.61 12.16 229 43589 68760 32400948
Haemolysis 69.94 12.16 68 43750 7673 32462035
Nocardiosis 69.90 12.16 50 43768 3681 32466027
Bronchopulmonary aspergillosis 69.57 12.16 89 43729 13598 32456110
Alanine aminotransferase increased 68.49 12.16 247 43571 78232 32391476
Factor V inhibition 66.02 12.16 20 43798 184 32469524
Brain abscess 65.99 12.16 44 43774 2890 32466818
Weight increased 65.62 12.16 16 43802 83647 32386061
Hydronephrosis 65.04 12.16 72 43746 9451 32460257
Immune reconstitution inflammatory syndrome 61.40 12.16 70 43748 9489 32460219
Electrocardiogram QT prolonged 60.47 12.16 152 43666 39489 32430219
COVID-19 pneumonia 59.68 12.16 66 43752 8654 32461054
Tubulointerstitial nephritis 55.73 12.16 97 43721 19480 32450228
Respiratory failure 53.35 12.16 285 43533 106897 32362811
Cerebrovascular accident 49.99 12.16 27 43791 86293 32383415
Anuria 48.18 12.16 66 43752 10771 32458937
COVID-19 48.03 12.16 122 43696 31893 32437815
Insomnia 47.85 12.16 39 43779 100309 32369399
Pruritus 47.84 12.16 317 43501 128385 32341323
Stevens-Johnson syndrome 47.25 12.16 88 43730 18621 32451087
Transaminases increased 46.89 12.16 104 43714 24924 32444784
Pain 46.63 12.16 116 43702 187440 32282268
Product use in unapproved indication 46.22 12.16 236 43582 86968 32382740
Liver injury 45.74 12.16 74 43744 14000 32455708
Inflammatory marker increased 43.91 12.16 38 43780 3691 32466017
Cross sensitivity reaction 43.09 12.16 26 43792 1434 32468274
Blood glucose increased 43.05 12.16 17 43801 65224 32404484
Disseminated intravascular coagulation 41.96 12.16 95 43723 23081 32446627
Ureteral disorder 41.92 12.16 14 43804 181 32469527
Klebsiella infection 40.56 12.16 52 43766 7960 32461748
Acute respiratory distress syndrome 39.73 12.16 98 43720 25155 32444553
Thrombocytopenia 39.15 12.16 337 43481 147962 32321746
Hospitalisation 39.10 12.16 9 43809 48962 32420746
Joint swelling 38.45 12.16 11 43807 51724 32417984
Anxiety 38.01 12.16 44 43774 95961 32373747
Abdominal discomfort 37.64 12.16 12 43806 52612 32417096
Meningitis bacterial 36.76 12.16 22 43796 1195 32468513
Hepatitis toxic 35.31 12.16 27 43791 2201 32467507
Fixed eruption 35.04 12.16 22 43796 1303 32468405
Urticaria 34.89 12.16 166 43652 59448 32410260
Flank pain 34.01 12.16 43 43775 6491 32463217
Cardiac failure congestive 33.47 12.16 39 43779 84813 32384895
Asthenia 32.98 12.16 185 43633 235759 32233949
Liver function test increased 32.87 12.16 60 43758 12500 32457208
Torsade de pointes 32.72 12.16 45 43773 7370 32462338
Crying 32.61 12.16 40 43778 5856 32463852
Alcohol intolerance 32.45 12.16 14 43804 377 32469331
Portal fibrosis 31.94 12.16 14 43804 392 32469316
Drug resistance 31.86 12.16 85 43733 22880 32446828
Choreoathetosis 31.75 12.16 19 43799 1032 32468676
Pain in extremity 31.54 12.16 71 43747 118830 32350878
Arthralgia 31.53 12.16 99 43719 148349 32321359
Drug interaction 31.22 12.16 439 43379 217746 32251962
Trichosporon infection 31.07 12.16 17 43801 778 32468930
Hepatitis cholestatic 30.56 12.16 46 43772 8179 32461529
Toxicity to various agents 30.41 12.16 130 43688 177911 32291797
Condition aggravated 30.36 12.16 332 43486 155329 32314379
Acute hepatic failure 30.28 12.16 59 43759 12910 32456798
Sphincter of Oddi dysfunction 30.03 12.16 10 43808 128 32469580
Malignant mesenteric neoplasm 29.97 12.16 8 43810 44 32469664
Neutropenia 29.96 12.16 308 43510 141867 32327841
Toxic skin eruption 29.79 12.16 55 43763 11559 32458149
Ascites 29.67 12.16 120 43698 40071 32429637
Pseudomembranous colitis 29.67 12.16 28 43790 3044 32466664
Coronary artery disease 29.57 12.16 15 43803 49691 32420017
Feeling abnormal 29.39 12.16 23 43795 60400 32409308
Rash morbilliform 29.39 12.16 27 43791 2837 32466871
Muscle spasms 29.26 12.16 31 43787 70387 32399321
Cardiac disorder 29.14 12.16 10 43808 41856 32427852
Clostridium difficile infection 28.99 12.16 70 43748 17726 32451982
Nasopharyngitis 28.91 12.16 26 43792 63761 32405947
Hepatomegaly 28.70 12.16 51 43767 10406 32459302
Hepatitis acute 28.61 12.16 42 43776 7303 32462405
Hepatic enzyme increased 28.48 12.16 112 43706 36925 32432783
Hyperferritinaemia 28.40 12.16 13 43805 404 32469304
Dry gangrene 28.25 12.16 13 43805 409 32469299
Ventricular fibrillation 28.10 12.16 68 43750 17242 32452466
Dehydration 28.09 12.16 85 43733 128873 32340835
Aspartate aminotransferase increased 27.98 12.16 169 43649 66260 32403448
Hypoxia 27.53 12.16 141 43677 51991 32417717
Drug intolerance 27.24 12.16 17 43801 50218 32419490
Kounis syndrome 27.20 12.16 22 43796 1946 32467762
Intentional overdose 27.17 12.16 11 43807 41590 32428118
Leukocytosis 26.83 12.16 81 43737 23386 32446322
Cyanosis 26.78 12.16 55 43763 12498 32457210
Headache 26.77 12.16 155 43663 196042 32273666
Jejunal ulcer perforation 26.76 12.16 8 43810 70 32469638
Hyper IgE syndrome 26.66 12.16 8 43810 71 32469637
Escherichia infection 26.54 12.16 40 43778 7120 32462588
Diarrhoea 26.51 12.16 340 43478 364462 32105246
Tachypnoea 26.26 12.16 65 43753 16718 32452990
Endocarditis 26.25 12.16 38 43780 6526 32463182
Janeway lesion 26.17 12.16 6 43812 15 32469693
Metastases to stomach 26.09 12.16 8 43810 77 32469631
Pleocytosis 25.67 12.16 13 43805 507 32469201
Encephalitis 25.61 12.16 39 43779 7005 32462703
Inappropriate schedule of product administration 25.56 12.16 15 43803 45810 32423898
Procalcitonin increased 25.49 12.16 20 43798 1693 32468015
Neurotoxicity 25.32 12.16 60 43758 15010 32454698
Myasthenia gravis crisis 25.21 12.16 13 43805 527 32469181
Drug ineffective for unapproved indication 25.15 12.16 57 43761 13855 32455853
Suicidal ideation 24.99 12.16 10 43808 38073 32431635
Hyponatraemia 24.96 12.16 179 43639 74334 32395374
Erythema 24.65 12.16 194 43624 82911 32386797
Angina pectoris 24.64 12.16 6 43812 31420 32438288
Enterobacter infection 24.44 12.16 22 43796 2251 32467457
Therapeutic product effect decreased 24.17 12.16 6 43812 31011 32438697
Chest pain 24.15 12.16 86 43732 124051 32345657
Bacterial pericarditis 24.08 12.16 7 43811 55 32469653
Drug effective for unapproved indication 24.05 12.16 18 43800 1421 32468287
Antimicrobial susceptibility test resistant 23.86 12.16 10 43808 250 32469458
Respiratory distress 23.49 12.16 102 43716 35144 32434564
Cerebral cyst 23.39 12.16 10 43808 263 32469445
Wrong technique in product usage process 23.34 12.16 9 43809 35050 32434658
Contusion 23.28 12.16 8 43810 33460 32436248
Crystalluria 23.28 12.16 12 43806 486 32469222
Sepsis 23.26 12.16 321 43497 158513 32311195
Psoriasis 23.14 12.16 17 43801 46106 32423602
Rash 23.00 12.16 403 43415 208930 32260778
Gait disturbance 22.99 12.16 46 43772 80362 32389346
Omental necrosis 22.96 12.16 6 43812 30 32469678
Coagulopathy 22.78 12.16 68 43750 19509 32450199
Infective chondritis 22.57 12.16 5 43813 10 32469698
Eastern Cooperative Oncology Group performance status 22.48 12.16 6 43812 33 32469675
Device related sepsis 22.19 12.16 22 43796 2541 32467167
Clostridium test positive 22.15 12.16 21 43797 2296 32467412
Jaundice 22.11 12.16 98 43720 34060 32435648
Candida infection 22.11 12.16 61 43757 16742 32452966
Weight decreased 22.05 12.16 131 43687 164687 32305021
Hypertension 21.99 12.16 97 43721 131653 32338055
Muscle abscess 21.87 12.16 12 43806 552 32469156
No adverse event 21.79 12.16 68 43750 19985 32449723
Stress 21.69 12.16 76 43742 23706 32446002
Tissue infiltration 21.59 12.16 7 43811 82 32469626
Malaise 21.53 12.16 145 43673 176993 32292715
Hepatic function abnormal 21.43 12.16 118 43700 44722 32424986
Blood alkaline phosphatase increased 21.42 12.16 93 43725 32039 32437669
Acute respiratory failure 21.38 12.16 86 43732 28642 32441066
Corynebacterium infection 21.37 12.16 11 43807 444 32469264
Coagulation factor decreased 21.21 12.16 7 43811 87 32469621
Bile duct stone 20.84 12.16 21 43797 2473 32467235
Type IV hypersensitivity reaction 20.84 12.16 16 43802 1312 32468396
Liver transplant failure 20.20 12.16 7 43811 102 32469606
Dry mouth 20.13 12.16 4 43814 24115 32445593
Mucormycosis 20.13 12.16 31 43787 5623 32464085
Prostate cancer 20.04 12.16 6 43812 27400 32442308
Malignant neoplasm progression 19.90 12.16 48 43770 78448 32391260
Oliguria 19.88 12.16 38 43780 8196 32461512
Serum sickness-like reaction 19.83 12.16 7 43811 108 32469600
Diabetes mellitus 19.77 12.16 19 43799 45154 32424554
Mobility decreased 19.40 12.16 7 43811 28402 32441306
Drug dependence 19.38 12.16 4 43814 23480 32446228
Pulmonary physical examination abnormal 19.30 12.16 5 43813 24 32469684
Balance disorder 19.21 12.16 15 43803 39444 32430264
Syncope 19.19 12.16 60 43758 90064 32379644
Memory impairment 18.95 12.16 16 43802 40463 32429245
Red blood cell schistocytes present 18.94 12.16 9 43809 305 32469403
Calculus urinary 18.93 12.16 15 43803 1288 32468420
Haemophagocytic lymphohistiocytosis 18.90 12.16 45 43773 11290 32458418
Vision blurred 18.86 12.16 19 43799 44167 32425541
Lymphopenia 18.55 12.16 52 43766 14404 32455304
Infective spondylitis 18.42 12.16 8 43810 219 32469489
Pneumonia bacterial 18.37 12.16 43 43775 10673 32459035
Antinuclear antibody negative 18.37 12.16 5 43813 30 32469678
Hyperamylasaemia 18.31 12.16 11 43807 602 32469106
Nail bed bleeding 18.23 12.16 5 43813 31 32469677
Neuropathy peripheral 18.03 12.16 49 43769 76933 32392775
Morganella infection 17.93 12.16 10 43808 475 32469233
Osteomyelitis fungal 17.86 12.16 8 43810 236 32469472
Overdose 17.82 12.16 59 43759 87018 32382690
Interleukin-2 receptor increased 17.79 12.16 7 43811 148 32469560
Dyspnoea 17.74 12.16 363 43455 361682 32108026
Vascular purpura 17.70 12.16 16 43802 1646 32468062
Bronchopleural fistula 17.65 12.16 10 43808 490 32469218
Asthma 17.64 12.16 20 43798 44045 32425663
Splenomegaly 17.53 12.16 51 43767 14426 32455282
Incorrect dose administered 17.46 12.16 13 43805 35015 32434693
Erythema nodosum 17.41 12.16 13 43805 1022 32468686
Drug eruption 17.26 12.16 61 43757 19105 32450603
Renal papillary necrosis 17.25 12.16 7 43811 161 32469547
Erectile dysfunction 17.18 12.16 3 43815 19836 32449872
Gastrooesophageal reflux disease 17.17 12.16 13 43805 34725 32434983
Peripheral swelling 17.15 12.16 42 43776 68303 32401405
Coronavirus infection 17.09 12.16 23 43795 3689 32466019
Prothrombin time ratio decreased 17.05 12.16 9 43809 383 32469325
Shock 17.00 12.16 71 43747 24043 32445665
Herpes zoster reactivation 16.98 12.16 8 43810 266 32469442
Suicide attempt 16.84 12.16 16 43802 38228 32431480
Faeces pale 16.84 12.16 15 43803 1514 32468194
Vanishing bile duct syndrome 16.60 12.16 11 43807 715 32468993
Transient ischaemic attack 16.55 12.16 7 43811 25787 32443921
Peritoneal dialysis 16.53 12.16 10 43808 554 32469154
Chondrocalcinosis 16.47 12.16 8 43810 285 32469423
Cataract 16.45 12.16 6 43812 24177 32445531
Disseminated cryptococcosis 16.16 12.16 13 43805 1141 32468567
Loss of personal independence in daily activities 16.10 12.16 8 43810 26825 32442883
ADAMTS13 activity decreased 16.09 12.16 6 43812 109 32469599
Gamma-glutamyltransferase increased 16.07 12.16 83 43735 30699 32439009
Unevaluable event 16.06 12.16 13 43805 33573 32436135
Carotid artery insufficiency 16.03 12.16 4 43814 16 32469692
Cholangitis 15.95 12.16 35 43783 8323 32461385
Cerebellar syndrome 15.87 12.16 17 43801 2149 32467559
Amnesia 15.74 12.16 7 43811 25029 32444679
Whipple's disease 15.65 12.16 4 43814 18 32469690
Aggression 15.63 12.16 18 43800 39371 32430337
Encephalopathy 15.60 12.16 89 43729 34168 32435540
Drug ineffective 15.60 12.16 648 43170 382829 32086879
Henoch-Schonlein purpura 15.59 12.16 15 43803 1670 32468038
Human T-cell lymphotropic virus type I infection 15.47 12.16 4 43814 19 32469689
Hypofibrinogenaemia 15.36 12.16 15 43803 1701 32468007
Hypoaesthesia 15.33 12.16 35 43783 58318 32411390
Nausea 15.32 12.16 323 43495 320526 32149182
Strongyloidiasis 15.18 12.16 18 43800 2543 32467165
Hepatitis fulminant 15.15 12.16 23 43795 4120 32465588
Intracranial pressure increased 15.14 12.16 22 43796 3791 32465917
Antibiotic level below therapeutic 15.02 12.16 5 43813 64 32469644
Back pain 14.98 12.16 88 43730 110965 32358743
Cholecystitis acute 14.97 12.16 28 43790 5942 32463766
Drug hypersensitivity 14.95 12.16 158 43660 73242 32396466
Orthostatic hypotension 14.87 12.16 8 43810 25642 32444066
Vitamin A deficiency 14.84 12.16 4 43814 23 32469685
Dermatitis exfoliative generalised 14.51 12.16 20 43798 3281 32466427
Basal cell carcinoma 14.48 12.16 3 43815 17565 32452143
Musculoskeletal pain 14.45 12.16 13 43805 31884 32437824
Metastases to heart 14.43 12.16 6 43812 147 32469561
Dermatitis bullous 14.32 12.16 29 43789 6524 32463184
Stomatitis 14.29 12.16 20 43798 40209 32429499
Contraindicated product administered 14.27 12.16 4 43814 19072 32450636
Bronchial haemorrhage 14.26 12.16 10 43808 713 32468995
Ototoxicity 14.26 12.16 14 43804 1598 32468110
Meningitis candida 14.23 12.16 5 43813 76 32469632
Red blood cell sedimentation rate decreased 14.17 12.16 5 43813 77 32469631
Tick-borne viral encephalitis 14.16 12.16 4 43814 28 32469680
Gonorrhoea 14.11 12.16 5 43813 78 32469630
Glucose-6-phosphate dehydrogenase deficiency 14.06 12.16 6 43812 157 32469551
Hypercreatininaemia 14.06 12.16 9 43809 551 32469157
Sleep apnoea syndrome 13.97 12.16 4 43814 18810 32450898
Fistula discharge 13.92 12.16 8 43810 403 32469305
Listeriosis 13.91 12.16 11 43807 942 32468766
Coagulation factor V level decreased 13.80 12.16 7 43811 274 32469434
Intentional product misuse 13.75 12.16 17 43801 36034 32433674
No reaction on previous exposure to drug 13.72 12.16 5 43813 85 32469623
Erythema annulare 13.70 12.16 4 43814 32 32469676
SJS-TEN overlap 13.68 12.16 7 43811 279 32469429
Haemodynamic instability 13.65 12.16 34 43784 8777 32460931
Influenza like illness 13.62 12.16 10 43808 27130 32442578
Psychotic disorder 13.61 12.16 7 43811 23013 32446695
Pneumococcal infection 13.60 12.16 8 43810 421 32469287
Osteonecrosis 13.37 12.16 3 43815 16619 32453089
Hypovolaemic shock 13.37 12.16 29 43789 6843 32462865
Hypocoagulable state 13.37 12.16 11 43807 997 32468711
Mechanical urticaria 13.35 12.16 5 43813 92 32469616
Local anaesthetic systemic toxicity 13.27 12.16 6 43812 181 32469527
Erythema multiforme 13.20 12.16 34 43784 8958 32460750
Hyperthermia 13.19 12.16 38 43780 10690 32459018
Neoplasm progression 13.16 12.16 5 43813 19653 32450055
Dependence on oxygen therapy 13.15 12.16 6 43812 185 32469523
Lower respiratory tract infection 13.15 12.16 12 43806 29231 32440477
COVID-19 treatment 13.13 12.16 7 43811 304 32469404
Haematuria traumatic 13.03 12.16 6 43812 189 32469519
Neuralgic amyotrophy 13.03 12.16 6 43812 189 32469519
Ureteric obstruction 13.02 12.16 12 43806 1266 32468442
White blood cell count decreased 12.98 12.16 71 43747 91127 32378581
Rash erythematous 12.81 12.16 65 43753 23874 32445834
Blood cholesterol increased 12.78 12.16 4 43814 17753 32451955
Haemorrhoids thrombosed 12.75 12.16 6 43812 199 32469509
Hyperglycaemia 12.74 12.16 20 43798 38371 32431337
Tuberculosis of genitourinary system 12.73 12.16 4 43814 42 32469666
Allergy test positive 12.69 12.16 3 43815 9 32469699
Altered state of consciousness 12.67 12.16 61 43757 21936 32447772
Osteonecrosis of jaw 12.62 12.16 5 43813 19161 32450547
Cholestatic liver injury 12.53 12.16 14 43804 1856 32467852
Leukopenia 12.51 12.16 130 43688 59992 32409716
Irritability 12.48 12.16 9 43809 24645 32445063
Shock haemorrhagic 12.41 12.16 37 43781 10608 32459100
Respiratory alkalosis 12.39 12.16 13 43805 1606 32468102
Pneumococcal sepsis 12.38 12.16 10 43808 883 32468825
Palmar-plantar erythrodysaesthesia syndrome 12.36 12.16 3 43815 15746 32453962
Ocular icterus 12.33 12.16 18 43800 3114 32466594
Procalcitonin abnormal 12.32 12.16 5 43813 115 32469593
Blood pressure increased 12.29 12.16 60 43758 79294 32390414
Pyelonephritis 12.25 12.16 26 43792 6043 32463665
Sphingomonas paucimobilis infection 12.25 12.16 4 43814 48 32469660
Drug withdrawal syndrome 12.19 12.16 6 43812 20225 32449483
Injection site pain 12.18 12.16 16 43802 33042 32436666
Polycystic liver disease 12.17 12.16 4 43814 49 32469659

Pharmacologic Action:

SourceCodeDescription
ATC J01DD04 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
OTHER BETA-LACTAM ANTIBACTERIALS
Third-generation cephalosporins
ATC J01DD54 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
OTHER BETA-LACTAM ANTIBACTERIALS
Third-generation cephalosporins
ATC J01DD63 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
OTHER BETA-LACTAM ANTIBACTERIALS
Third-generation cephalosporins
FDA CS M0003827 Cephalosporins
FDA EPC N0000175488 Cephalosporin Antibacterial
MeSH PA D000900 Anti-Bacterial Agents
MeSH PA D000890 Anti-Infective Agents
CHEBI has role CHEBI:35625 beta-lactamase inhibitors
CHEBI has role CHEBI:36047 antibacterial drugs
CHEBI has role CHEBI:88188 allergenic drug

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Gonococcal meningitis indication 151004
Streptococcal meningitis indication 4510004 DOID:11574
Septicemia due to Escherichia coli indication 9323009
Bacterial septicemia indication 10001005 DOID:0040085
Staphylococcal meningitis indication 12166008
Gonorrhea indication 15628003 DOID:7551
Infection of skin AND/OR subcutaneous tissue indication 19824006
Acute gonococcal cervicitis indication 20943002 DOID:10615
Staphylococcal pneumonia indication 22754005
Streptococcal septicemia indication 29577008
Acute gonococcal urethritis indication 29864006
Pneumonia due to Streptococcus indication 34020007
Gonorrhea of rectum indication 42746002
Gonococcal infection of joint indication 44743006
Bacterial arthritis indication 48245008
Salmonella septicemia indication 49786009
Lower respiratory tract infection indication 50417007
Pneumococcal meningitis indication 51169003
Pneumonia due to Escherichia coli indication 51530003
Bacterial pneumonia indication 53084003 DOID:874
Klebsiella cystitis indication 60867007
Gonococcal endocarditis indication 61048000
Acute gonococcal endometritis indication 65295003 DOID:7527
Haemophilus influenzae pneumonia indication 70036007
Infection due to Escherichia coli indication 71057007
Bacterial infection due to Serratia indication 71120004
Rhinoscleroma indication 72409005 DOID:11336
Gonorrhea of pharynx indication 74372003
Endometritis indication 78623009 DOID:1002
Bacterial meningitis indication 95883001 DOID:9470
Infection of bone indication 111253001
Staphylococcal septicemia indication 111821004
Female genital tract infection indication 125585007
Infectious disease of abdomen indication 128070006
Infection due to Enterobacteriaceae indication 128945009
Bacterial infection due to Klebsiella pneumoniae indication 186435004
Meningococcal meningitis indication 192644005
Escherichia coli meningitis indication 192655005
Proteus pneumonia indication 195888009
Chancroid indication 266143009 DOID:13778
Escherichia coli urinary tract infection indication 301011002
Proteus urinary tract infection indication 301012009
Streptococcus pyogenes infection indication 302809008
Bacterial urinary infection indication 312124009
Infective otitis media indication 312218008
Infectious disorder of joint indication 363162000
Meningitis due to Klebsiella mobilis indication 420585007
Peptostreptococcus infection indication 135341000119101
Klebsiella Pneumoniae Osteomyelitis indication
Inflammatory Disease of Female Pelvic Organs indication
Proteus Mirabilis Osteomyelitis indication
Peptostreptococcus Peritonitis indication
Enterobacter Pneumonia indication
Proteus Joint Infection indication
Haemophilus Septic Arthritis indication
Skin and Skin Structure Serratia Infection indication
E. Coli Peritonitis indication
Prevention of Perioperative Infection indication
Haemophilus Influenzae Type B Infections indication
Adult Gonococcal Conjunctivitis indication
E. Coli Septic Arthritis indication
Haemophilus Septicemia indication
Disseminated Gonococcal Infection indication
Klebsiella Pneumoniae Peritonitis indication
H. Influenzae Meningitis indication
Prevention of Meningococcal Meningitis indication
Gram-Negative Aerobic Bacillary Pneumonia indication
Skin and Skin Structure Proteus Infection indication
Haemophilus Osteomyelitis indication
Haemophilus Parainfluenzae Pneumonia indication
Enterobacter Osteomyelitis indication
Streptococcal Joint Infection indication
Pelvic Inflammatory Disease with Neisseria Gonorrhea indication
Klebsiella Joint Infection indication
EnterobacterJoint Infection indication
Skin and Skin Structure Morganella Morganii Infection indication
Streptococcus Osteomyelitis indication
E. Coli Joint Infection indication
E. Coli Osteomyelitis indication
Pyrexia of unknown origin off-label use 7520000
Lyme disease off-label use 23502006 DOID:11729
Lyme arthritis off-label use 33937009
Pseudotuberculosis off-label use 36753006
Lyme carditis off-label use 77863005
Infection by Yersinia enterocolitica off-label use 80960004
Ventilator-acquired pneumonia off-label use 429271009
Lyme Disease of the Central Nervous System off-label use
Sexual Transmitted Disease Exposure from Sexual Assault off-label use
Disorder of gallbladder contraindication 39621005 DOID:0060262
Acute nephropathy contraindication 58574008
Hemolytic anemia contraindication 61261009 DOID:583
Disease of liver contraindication 235856003 DOID:409
Neonatal hyperbilirubinemia contraindication 281610001
Pseudomembranous enterocolitis contraindication 397683000

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 2.65 acidic
pKa2 4.17 acidic
pKa3 13.31 acidic
pKa4 3.29 Basic
pKa5 0.93 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
D-amino-acid oxidase Enzyme IC50 5 CHEMBL
Peptidoglycan synthase FtsI Enzyme INHIBITOR IC50 6.14 WOMBAT-PK CHEMBL
Penicillin-binding protein 1A Enzyme INHIBITOR IC50 6.51 WOMBAT-PK CHEMBL
Penicillin-binding protein 1B Enzyme INHIBITOR IC50 5.74 WOMBAT-PK CHEMBL
Penicillin-binding protein 2 Enzyme INHIBITOR IC50 6.21 WOMBAT-PK CHEMBL

External reference:

IDSource
4019667 VUID
N0000147759 NUI
D00924 KEGG_DRUG
104376-79-6 SECONDARY_CAS_RN
C0007561 UMLSCUI
CHEBI:29007 CHEBI
9F2 PDB_CHEM_ID
CHEMBL1200995 ChEMBL_ID
CHEMBL161 ChEMBL_ID
CHEMBL3183968 ChEMBL_ID
D002443 MESH_DESCRIPTOR_UI
DB01212 DRUGBANK_ID
5326 IUPHAR_LIGAND_ID
4923 INN_ID
75J73V1629 UNII
5479530 PUBCHEM_CID
203172 RXNORM
1314 MMSL
4387 MMSL
69782 MMSL
d00052 MMSL
002734 NDDF
004849 NDDF
19841008 SNOMEDCT_US
33440000 SNOMEDCT_US
372670001 SNOMEDCT_US
4017814 VANDF
4019667 VANDF

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Ceftriaxone HUMAN PRESCRIPTION DRUG LABEL 1 0143-9678 INJECTION, POWDER, FOR SOLUTION 10 g INTRAVENOUS ANDA 26 sections
Ceftriaxone HUMAN PRESCRIPTION DRUG LABEL 1 0143-9768 INJECTION, POWDER, FOR SOLUTION 10 g INTRAVENOUS ANDA 23 sections
Ceftriaxone HUMAN PRESCRIPTION DRUG LABEL 1 0143-9856 INJECTION, POWDER, FOR SOLUTION 2 g INTRAMUSCULAR ANDA 24 sections
Ceftriaxone HUMAN PRESCRIPTION DRUG LABEL 1 0143-9857 INJECTION, POWDER, FOR SOLUTION 1 g INTRAMUSCULAR ANDA 24 sections
Ceftriaxone HUMAN PRESCRIPTION DRUG LABEL 1 0143-9858 INJECTION, POWDER, FOR SOLUTION 500 mg INTRAMUSCULAR ANDA 24 sections
Ceftriaxone HUMAN PRESCRIPTION DRUG LABEL 1 0143-9859 INJECTION, POWDER, FOR SOLUTION 250 mg INTRAMUSCULAR ANDA 24 sections
CEFTRIAXONE AND DEXTROSE HUMAN PRESCRIPTION DRUG LABEL 1 0264-3153 INJECTION, SOLUTION 1 g INTRAVENOUS NDA 27 sections
CEFTRIAXONE AND DEXTROSE HUMAN PRESCRIPTION DRUG LABEL 1 0264-3155 INJECTION, SOLUTION 2 g INTRAVENOUS NDA 27 sections
Ceftriaxone HUMAN PRESCRIPTION DRUG LABEL 1 0338-5002 INJECTION, SOLUTION 1 g INTRAVENOUS ANDA 23 sections
Ceftriaxone HUMAN PRESCRIPTION DRUG LABEL 1 0338-5003 INJECTION, SOLUTION 2 g INTRAVENOUS ANDA 23 sections
Ceftriaxone Sodium HUMAN PRESCRIPTION DRUG LABEL 1 0409-7332 INJECTION, POWDER, FOR SOLUTION 1 g INTRAVENOUS ANDA 24 sections
Ceftriaxone Sodium HUMAN PRESCRIPTION DRUG LABEL 1 0409-7332 INJECTION, POWDER, FOR SOLUTION 1 g INTRAVENOUS ANDA 24 sections
Ceftriaxone Sodium HUMAN PRESCRIPTION DRUG LABEL 1 0409-7333 INJECTION, POWDER, FOR SOLUTION 1 g INTRAVENOUS ANDA 21 sections
Ceftriaxone Sodium HUMAN PRESCRIPTION DRUG LABEL 1 0409-7333 INJECTION, POWDER, FOR SOLUTION 1 g INTRAVENOUS ANDA 21 sections
Ceftriaxone Sodium HUMAN PRESCRIPTION DRUG LABEL 1 0409-7334 INJECTION, POWDER, FOR SOLUTION 10 g INTRAVENOUS ANDA 25 sections
Ceftriaxone Sodium HUMAN PRESCRIPTION DRUG LABEL 1 0409-7334 INJECTION, POWDER, FOR SOLUTION 10 g INTRAVENOUS ANDA 25 sections
Ceftriaxone Sodium HUMAN PRESCRIPTION DRUG LABEL 1 0409-7335 INJECTION, POWDER, FOR SOLUTION 2 g INTRAVENOUS ANDA 24 sections
Ceftriaxone Sodium HUMAN PRESCRIPTION DRUG LABEL 1 0409-7335 INJECTION, POWDER, FOR SOLUTION 2 g INTRAVENOUS ANDA 24 sections
Ceftriaxone Sodium HUMAN PRESCRIPTION DRUG LABEL 1 0409-7336 INJECTION, POWDER, FOR SOLUTION 2 g INTRAVENOUS ANDA 21 sections
Ceftriaxone Sodium HUMAN PRESCRIPTION DRUG LABEL 1 0409-7336 INJECTION, POWDER, FOR SOLUTION 2 g INTRAVENOUS ANDA 21 sections
Ceftriaxone Sodium HUMAN PRESCRIPTION DRUG LABEL 1 0409-7337 INJECTION, POWDER, FOR SOLUTION 250 mg INTRAMUSCULAR ANDA 24 sections
Ceftriaxone Sodium HUMAN PRESCRIPTION DRUG LABEL 1 0409-7337 INJECTION, POWDER, FOR SOLUTION 250 mg INTRAMUSCULAR ANDA 24 sections
Ceftriaxone Sodium HUMAN PRESCRIPTION DRUG LABEL 1 0409-7338 INJECTION, POWDER, FOR SOLUTION 500 mg INTRAMUSCULAR ANDA 24 sections
Ceftriaxone Sodium HUMAN PRESCRIPTION DRUG LABEL 1 0409-7338 INJECTION, POWDER, FOR SOLUTION 500 mg INTRAMUSCULAR ANDA 24 sections
Ceftriaxone Sodium HUMAN PRESCRIPTION DRUG LABEL 1 0781-3206 INJECTION, POWDER, FOR SOLUTION 250 mg INTRAMUSCULAR ANDA 26 sections
Ceftriaxone Sodium HUMAN PRESCRIPTION DRUG LABEL 1 0781-3207 INJECTION, POWDER, FOR SOLUTION 500 mg INTRAMUSCULAR ANDA 26 sections
Ceftriaxone Sodium HUMAN PRESCRIPTION DRUG LABEL 1 0781-3208 INJECTION, POWDER, FOR SOLUTION 1 g INTRAVENOUS ANDA 26 sections
Ceftriaxone Sodium HUMAN PRESCRIPTION DRUG LABEL 1 0781-3209 INJECTION, POWDER, FOR SOLUTION 2 g INTRAVENOUS ANDA 26 sections
Ceftriaxone Sodium HUMAN PRESCRIPTION DRUG LABEL 1 0781-3210 INJECTION, POWDER, FOR SOLUTION 10 g INTRAVENOUS ANDA 24 sections
Ceftriaxone Sodium HUMAN PRESCRIPTION DRUG LABEL 1 21695-202 INJECTION, POWDER, FOR SOLUTION 500 mg INTRAVENOUS ANDA 23 sections